Exploring the impact of excessive daytime sleepiness caused by obstructive sleep apnea on patient and partner quality of life: a time trade-off utility study in the UK general public.

cost–benefit analysis health care economics quality of life sleep apnea syndromes sleepiness

Journal

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
ISSN: 1550-9397
Titre abrégé: J Clin Sleep Med
Pays: United States
ID NLM: 101231977

Informations de publication

Date de publication:
01 09 2022
Historique:
pubmed: 15 6 2022
medline: 9 9 2022
entrez: 14 6 2022
Statut: ppublish

Résumé

This study aimed to quantify the impact of excessive daytime sleepiness (EDS) on patient and patient's partner health-related quality of life in the form of utility values typically used in health economic evaluations. A time trade-off study was conducted in a UK general population sample (representing a societal perspective) to elicit utility values, measured on a 0 to 1 scale, for health states with varying obstructive sleep apnea-associated EDS severity. In a time trade-off study, health states are described, and participants "trade off" time in a specific higher severity state for a shorter amount of time in full health. Overall, the sample consisted of 104 participants, who were interviewed and took part in the time trade-off exercise to elicit utility values for patient and partner residual EDS health states. The average utility score declined with increasing obstructive sleep apnea-associated EDS severity for both patient (no EDS, 0.926; mild EDS, 0.794; moderate EDS, 0.614; severe EDS, 0.546) and partner (no EDS, 0.955; mild EDS, 0.882; moderate EDS, 0.751; severe EDS, 0.670) health states. These results demonstrate the high impact that EDS in obstructive sleep apnea is estimated to have on patient and partner health-related quality of life. Tolley K, Noble-Longster J, Mettam S, et al. Exploring the impact of excessive daytime sleepiness caused by obstructive sleep apnea on patient and partner quality of life: a time trade-off utility study in the UK general public.

Identifiants

pubmed: 35698455
pii: jcsm.10092
doi: 10.5664/jcsm.10092
pmc: PMC9435341
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2237-2246

Informations de copyright

© 2022 American Academy of Sleep Medicine.

Références

J Sleep Res. 2013 Aug;22(4):389-97
pubmed: 23409736
Sleep Med Clin. 2019 Dec;14(4):431-439
pubmed: 31640871
J Patient Rep Outcomes. 2017;2(1):20
pubmed: 29757323
J Clin Sleep Med. 2014 Sep 15;10(9):1039-40
pubmed: 25221449
Sleep. 1996 Sep;19(7):583-8
pubmed: 8899938
J Med Econ. 2012;15(6):1192-200
pubmed: 22804691
Eur J Health Econ. 2013 Oct;14(5):749-59
pubmed: 22941034
Arch Intern Med. 2003 Mar 10;163(5):565-71
pubmed: 12622603
Front Neurol. 2018 Jun 27;9:505
pubmed: 29997573
Eur J Health Econ. 2013 Jul;14 Suppl 1:S53-64
pubmed: 23900665
Sleep. 2001 Feb 1;24(1):96-105
pubmed: 11204058
Health Qual Life Outcomes. 2014 Apr 09;12:48
pubmed: 24716709
J Thorac Dis. 2015 Aug;7(8):1311-22
pubmed: 26380759
Ann Am Thorac Soc. 2020 Aug;17(8):998-1007
pubmed: 32353246
Eur Respir J. 2009 May;33(5):1062-7
pubmed: 19407048
Am J Respir Crit Care Med. 2019 Jun 1;199(11):1421-1431
pubmed: 30521757
Int J Environ Res Public Health. 2018 Jul 26;15(8):
pubmed: 30049991
Health Qual Life Outcomes. 2015 Nov 16;13:181
pubmed: 26573610
Pharmacoecon Open. 2022 Mar;6(2):231-239
pubmed: 34532843
Sleep. 2005 Apr;28(4):464-71
pubmed: 16171291
Qual Life Res. 2019 May;28(5):1191-1199
pubmed: 30767088
Health Technol Assess. 2009 Jan;13(4):iii-iv, xi-xiv, 1-119, 143-274
pubmed: 19103134
Clin Ther. 2006 May;28(5):689-706
pubmed: 16861091
Eur J Gastroenterol Hepatol. 2018 Feb;30(2):174-180
pubmed: 29194233
Ther Adv Chronic Dis. 2015 Sep;6(5):273-85
pubmed: 26336596

Auteurs

Keith Tolley (K)

Tolley Health Economics, Buxton, United Kingdom.

Joanne Noble-Longster (J)

Tolley Health Economics, Buxton, United Kingdom.

Sam Mettam (S)

Jazz Pharmaceuticals, Oxford, United Kingdom.

Rachel Hibbs (R)

Tolley Health Economics, Buxton, United Kingdom.

Matthew Cawson (M)

Tolley Health Economics, Buxton, United Kingdom.

Luke Stainer (L)

Tolley Health Economics, Buxton, United Kingdom.

Tom Snell (T)

Tolley Health Economics, Buxton, United Kingdom.

Ari Manuel (A)

University Hospital Aintree, Liverpool, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH